Gerhard Koenig, Arkuda CEO

At­las-backed neu­rol­o­gy play­er Arku­da reemerges from the grind­stone with a lead pro­gran­ulin drug ap­proach­ing the clin­ic

In the bustling biotech space, a cou­ple years can feel like an eter­ni­ty — but for an At­las Ven­ture-backed neu­rol­o­gy play­er with a nov­el spin on R&D, a few qui­et years aren’t the worst thing in the world.

Arku­da Ther­a­peu­tics closed a $64 mil­lion Se­ries B round co-led by Cor­morant As­set Man­age­ment and Piv­otal bioVen­ture Part­ners with a lead mod­u­la­tor tar­get­ing fron­totem­po­ral de­men­tia (FTD) edg­ing clos­er to the clin­ic, the com­pa­ny said.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.